Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins

被引：91

作者：

Kwak, BR ^{[1
]}

Mulhaupt, F ^{[1
]}

Mach, F ^{[1
]}

机构：

[1] Univ Hosp, Div Cardiol, Fdn Med Res, Fac Med, CH-1211 Geneva 4, Switzerland

来源：

AUTOIMMUNITY REVIEWS | 2003年 / 2卷 / 06期

关键词：

atherosclerosis; statins; cholesterol-lowering; inflammation; immunomodulation;

D O I：

10.1016/S1568-9972(03)00049-1

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Large clinical trials have demonstrated that HMG-CoA reductase inhibitors or 'statins' greatly reduce cardiovascular-related morbidity and mortality. The beneficial effects of statins were first assumed to result from their ability to reduce cholesterol synthesis and improve serum lipid profiles. In recent years, however, numerous pleiotropic effects of statins on atherosclerotic lesions have been described. In this review, we summarize the actions of statins on different aspects of atherosclerotic plaque development. These include endothelial dysfunction, leukocyte recruitment and inflammation, smooth muscle cell activation/proliferation, and finally plaque rupture and thrombosis. (C) 2003 Elsevier Science B.V. All rights reserved.

引用

页码：332 / 338

页数：7

共 40 条

[31] HMG COA REDUCTASE INHIBITORS - INVIVO EFFECTS ON CAROTID INTIMAL THICKENING IN NORMOCHOLESTEROLEMIC RABBITS [J].

SOMA, MR ;

DONETTI, E ;

PAROLINI, C ;

MAZZINI, G ;

FERRARI, C ;

FUMAGALLI, R ;

PAOLETTI, R .

ARTERIOSCLEROSIS AND THROMBOSIS, 1993, 13 (04) :571-578

[32] Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering [J].

Sparrow, CP ;

Burton, CA ;

Hernandez, M ;

Mundt, S ;

Hassing, H ;

Patel, S ;

Rosa, R ;

Hermanowski-Vosatka, A ;

Wang, PR ;

Zhang, DH ;

Peterson, L ;

Detmers, PA ;

Chao, YS ;

Wright, SD .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (01) :115-121

[33] A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid [J].

Stalker, TJ ;

Lefer, AM ;

Scalia, R .

BRITISH JOURNAL OF PHARMACOLOGY, 2001, 133 (03) :406-412

[34]

STASRK WW, 1998, AM J PHYSIOL, V275, pL55

[35] Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors [J].

Takemoto, M ;

Liao, JK .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (11) :1712-1719

[36] The evolving role of statins in the management of atherosclerosis [J].

Vaughan, CJ ;

Gotto, AM ;

Basson, CT .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (01) :1-10

[37] HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia [J].

Weber, C ;

Erl, W ;

Weber, KSC ;

Weber, PC .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (05) :1212-1217

[38] Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site [J].

Weitz-Schmidt, G ;

Welzenbach, K ;

Brinkmann, V ;

Kamata, T ;

Kallen, J ;

Bruns, C ;

Cottens, S ;

Takada, Y ;

Hommel, U .

NATURE MEDICINE, 2001, 7 (06) :687-692

[39] Simvastatin reduces graft vessel disease and mortality after heart transplantation - A four-year randomized trial [J].

Wenke, K ;

Meiser, B ;

Thiery, J ;

Nagel, D ;

vonScheidt, W ;

Steinbeck, G ;

Seidel, D ;

Reichart, B .

CIRCULATION, 1997, 96 (05) :1398-1402

[40] Modulation of inflammatory mediators and PPARγ and NFκB expression by pravastatin in response to lipoproteins in human monocytes in vitro [J].

Zelvyte, I ;

Dominaitiene, R ;

Crisby, M ;

Janciauskiene, S .

PHARMACOLOGICAL RESEARCH, 2002, 45 (02) :147-154

← 1 2 3 4 →